Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352658 | 0.89 | TLR7 (0.39) | TLR7TLR8ALDH1A1HTTMEN1 | |
| SCHEMBL27666505 | 0.87 | TLR7 (0.44) | TLR7TLR8HTTGAAGLA | |
| SCHEMBL3353817 | 0.86 | SMN1; SMN2 (0.56) | TLR7TLR8ALDH1A1MEN1KMT2A | |
| SCHEMBL27483682 | 0.84 | TLR7 (0.46) | TLR7TLR8ALDH1A1MEN1KMT2A | |
| SCHEMBL5618891 | 0.84 | GAA (0.43) | TLR7TLR8ALDH1A1HTTMEN1 | |
| SCHEMBL5617942 | 0.83 | ENPP2 (0.44) | TLR7TLR8ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3350626 | 0.83 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL5618924 | 0.82 | ENPP2 (0.43) | TLR7TLR8ALDH1A1HTTMEN1 | |
| SCHEMBL5618823 | 0.82 | TNF (0.47) | TLR7ALDH1A1HTTGAA | |
| SCHEMBL4793412 | 0.82 | SMN1; SMN2 (0.45) | TLR7TLR8ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678918-B2 | Intermediates for imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-06-15 | — | — | US | disclosed |
| US-7038051-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050288320-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-6949646-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050107421-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6894165-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-6624172-B2 | Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20030096998-A1 | Imidazonaphtyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20030083500-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-6518280-B2 | Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6514985-B1 | Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020173654-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020173653-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-1040112-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999029693-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | IFNG, IRF3, MAVS | TLR7 135/4885TLR8 182/4885ALDH1A1 2379/4885 |
| US-20030083500-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885TLR8 186/4885ALDH1A1 2677/4885 |
| US-20030096998-A1 | Imidazonaphtyridines | IFNG, IRF3, IFNAR1 | TLR7 96/4885TLR8 172/4885ALDH1A1 2676/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | TLR7 109/4885TLR8 186/4885ALDH1A1 2677/4885 |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | IFNG, IRF3, MAVS | TLR7 135/4885TLR8 182/4885ALDH1A1 2379/4885 |
| US-20020173653-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885TLR8 186/4885ALDH1A1 2677/4885 |
| US-20020173654-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885TLR8 186/4885ALDH1A1 2677/4885 |
| US-20050288320-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | TLR7 109/4885TLR8 186/4885ALDH1A1 2677/4885 |
| US-20050107421-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885TLR8 186/4885ALDH1A1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.